Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, Quinn CT, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ Jr, Rettig EM, Jo VY, Wong KS, Lizotte P, Paweletz CP, Uppaluri R, Haddad RI, Cohen EEW, Alexandrov LB, William WN Jr, Lippman SM, Woo SB. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2023 Nov 16:e234853. doi: 10.1001/jamaoncol.2023.4853. Online ahead of print. PMID: 37971722
Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, Quinn CT, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ Jr, Rettig EM, Jo VY, Wong KS, Lizotte P, Paweletz CP, Uppaluri R, Haddad RI, Cohen EEW, Alexandrov LB, William WN Jr, Lippman SM, Woo SB. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2023 Nov 16:e234853. doi: 10.1001/jamaoncol.2023.4853. Online ahead of print. PMID: 37971722

Year

Odintsov I, Makarem M, Nishino M, Bachert SE, Zhang T, LoPiccolo J, Paweletz CP, Gokhale PC, Ivanova E, Saldanha A, Rudin CM, Lockwood WW, Ladanyi M, Somwar R, Jänne PA, Sholl LM. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC. J Thorac Oncol. 2024 May;19(5):732-748. doi: 10.1016/j.jtho.2023.12.019. Epub 2023 Dec 26. PMID: 38154514

Tani T, Mathsyaraja H, Campisi M, Li ZH, Haratani K, Fahey CG, Ota K, Mahadevan NR, Shi Y, Saito S, Mizuno K, Thai TC, Sasaki N, Homme M, Yusuf CFB, Kashishian A, Panchal J, Wang M, Wolf BJ, Barbie TU, Paweletz CP, Gokhale PC, Liu D, Uppaluri R, Kitajima S, Cain J, Barbie DA. TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity. Cancer Discov. 2024 May 1;14(5):752-765. doi: 10.1158/2159-8290.CD-23-0700. PMID: 38227896

Singh H, Sahgal P, Kapner K, Corsello SM, Gupta H, Gujrathi R, Li YY, Cherniack AD, El Alam R, Kerfoot J, Andrews E, Lee A, Nambiar C, Hannigan AM, Remland J, Brais L, Leahy ME, Rubinson DA, Schlechter BL, Meyerson M, Kuang Y, Paweletz CP, Lee JK, Quintanilha JCF, Aguirre AJ, Perez KJ, Huffman BM, Rossi H, Abrams TA, Kabraji S, Trusolino L, Bertotti A, Sicinska ET, Parikh AR, Wolpin BM, Schrock AB, Giannakis M, Ng K, Meyerhardt JA, Hornick JL, Sethi NS, Cleary JM. RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer. Clin Cancer Res. 2024 Apr 15;30(8):1669-1684. doi: 10.1158/1078-0432.CCR-23-2581. PMID: 38345769

Lechner A, Rai A, Rojas-Rudilla V, Kuang Y, Paweletz CP, Sholl LM, Dong F. Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer. Arch Pathol Lab Med. 2024 May 1;148(5):553-558. doi: 10.5858/arpa.2023-0088-OA. PMID: 37639432

Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, Tchekmedyian V, Ruiz ES, Waldman AH, Schmults CD, Riella LV, Lizotte P, Paweletz CP, Chandraker AK, Murakami N, Silk AW. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma. J Clin Oncol. 2024 Mar 20;42(9):1021-1030. doi: 10.1200/JCO.23.01498. Epub 2024 Jan 22. PMID: 38252908

Wang Y, Buck A, Piel B, Zerefa L, Murugan N, Coherd CD, Miklosi AG, Johal H, Bastos RN, Huang K, Ficial M, Laimon YN, Signoretti S, Zhong Z, Hoang SM, Kastrunes GM, Grimaud M, Fayed A, Yuan HC, Nguyen QD, Thai T, Ivanova EV, Paweletz CP, Wu MR, Choueiri TK, Wee JO, Freeman GJ, Barbie DA, Marasco WA. Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects. Mol Cancer. 2024 Mar 16;23(1):56. doi: 10.1186/s12943-024-01952-w. PMID: 38491381

Ben-Ami R, Wang QL, Zhang J, Supplee JG, Fahrmann JF, Lehmann-Werman R, Brais LK, Nowak J, Yuan C, Loftus M, Babic A, Irajizad E, Davidi T, Zick A, Hubert A, Neiman D, Piyanzin S, Gal-Rosenberg O, Horn A, Shemer R, Glaser B, Boos N, Jajoo K, Lee L, Clancy TE, Rubinson DA, Ng K, Chabot JA, Kastrinos F, Kluger M, Aguirre AJ, Jänne PA, Bardeesy N, Stanger B, O’Hara MH, Till J, Maitra A, Carpenter EL, Bullock AJ, Genkinger J, Hanash SM, Paweletz CP, Dor Y, Wolpin BM. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut. 2024 Mar 7;73(4):639-648. doi: 10.1136/gutjnl-2023-331074. PMID: 38123998

Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, Quinn CT, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ Jr, Rettig EM, Jo VY, Wong KS, Lizotte P, Paweletz CP, Uppaluri R, Haddad RI, Cohen EEW, Alexandrov LB, William WN Jr, Lippman SM, Woo SB. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2024 Jan 1;10(1):32-41. doi: 10.1001/jamaoncol.2023.4853. PMID: 37971722

Chiaramida A, Obwar SG, Nordstrom AEH, Ericsson M, Saldanha A, Ivanova EV, Griffin GK, Khan DH, Belizaire R. Sensitivity to targeted UBA1 inhibition in a myeloid cell line model of VEXAS syndrome. Blood Adv. 2023 Dec 26;7(24):7445-7456. doi: 10.1182/bloodadvances.2023010531. PMID: 38091008

Li Y, Mahadevan NR, Duplaquet L, Hong D, Durmaz YT, Jones KL, Cho H, Morrow M, Protti A, Poitras MJ, Springer BF, Bronson RT, Gong X, Hui YH, Du J, Southard J, Thai T, Li S, Lizotte PH, Gokhale PC, Nguyen QD, Oser MG. Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1. Cell Rep Med. 2023 Nov 21;4(11):101282. doi: 10.1016/j.xcrm.2023.101282. PMID: 37992688

Hanna GJ, Villa A, Nandi SP, Shi R, ONeill A, Liu M, Quinn CT, Treister NS, Sroussi HY, Vacharotayangul P, Goguen LA, Annino DJ Jr, Rettig EM, Jo VY, Wong KS, Lizotte P, Paweletz CP, Uppaluri R, Haddad RI, Cohen EEW, Alexandrov LB, William WN Jr, Lippman SM, Woo SB. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2023 Nov 16:e234853. doi: 10.1001/jamaoncol.2023.4853. Online ahead of print. PMID: 37971722

Oliveira G, Egloff AM, Afeyan AB, Wolff JO, Zeng Z, Chernock RD, Zhou L, Messier C, Lizotte P, Pfaff KL, Stromhaug K, Penter L, Haddad RI, Hanna GJ, Schoenfeld JD, Goguen LA, Annino DJ, Jo V, Oppelt P, Pipkorn P, Jackson R, Puram SV, Paniello RC, Rich JT, Webb J, Zevallos JP, Mansour M, Fu J, Dunn GP, Rodig SJ, Ley J, Morris LGT, Dunn L, Paweletz CP, Kallogjeri D, Piccirillo JF, Adkins DR, Wu CJ, Uppaluri R. Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer. Sci Immunol. 2023 Sep 8;8(87):eadf4968. doi: 10.1126/sciimmunol.adf4968. Epub 2023 Sep 8. PMID: 37683037

Lechner A, Rai A, Rojas-Rudilla V, Kuang Y, Paweletz CP, Sholl LM, Dong F. Atypical Droplet Digital Polymerase Chain Reaction Patterns That Indicate Uncommon but Clinically Actionable EGFR Mutations in Lung Cancer. Arch Pathol Lab Med. 2023 Aug 28. doi: 10.5858/arpa.2023-0088-OA. Online ahead of print. PMID: 37639432

Gerton TJ, Green A, Campisi M, Chen M, Gjeci I, Mahadevan N, Lee CAA, Mishra R, Vo HV, Haratani K, Li ZH, Hasselblatt KT, Testino B, Connor T, Lian CG, Elias KM, Lizotte P, Ivanova EV, Barbie DA, Dinulescu DM. Development of a Patient-Derived 3D Immuno-Oncology Platform to Potentiate Immunotherapy Responses in Ascites-Derived Circulating Tumor Cells. Cancers (Basel). 2023 Aug 16;15(16):4128. doi: 10.3390/cancers15164128. PMID: 37627156

Nardi F, Perurena N, Schade AE, Li ZH, Ngo K, Ivanova EV, Saldanha A, Li C, Gokhale PC, Hata AN, Barbie DA, Paweletz CP, Jänne PA, Cichowski K. Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. J Clin Invest. 2023 Aug 15;133(16):e167651. doi: 10.1172/JCI167651. PMID: 37384411

Paweletz CP, Heavey GA, Kuang Y, Durlacher E, Kheoh T, Chao RC, Spira AI, Leventakos K, Johnson ML, Ou SI, Riely GJ, Anderes K, Yang W, Christensen JG, Jänne PA. Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients. Clin Cancer Res. 2023 Aug 15;29(16):3074-3080. doi: 10.1158/1078-0432.CCR-23-0795. PMID: 37279096

Khalsa JK, Cha J, Utro F, Naeem A, Murali I, Kuang Y, Vasquez K, Li L, Tyekucheva S, Fernandes SM, Veronese L, Guieze R, Sasi BK, Wang Z, Machado JH, Bai H, Alasfour M, Rhrissorrakrai K, Levovitz C, Danysh BP, Slowik K, Jacobs RA, Davids MS, Paweletz CP, Leshchiner I, Parida L, Getz G, Brown JR. Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples. Blood. 2023 Aug 3;142(5):421-433. doi: 10.1182/blood.2022016600. PMID: 37146250

Sun Y, Revach OY, Anderson S, Kessler EA, Wolfe CH, Jenney A, Mills CE, Robitschek EJ, Davis TGR, Kim S, Fu A, Ma X, Gwee J, Tiwari P, Du PP, Sindurakar P, Tian J, Mehta A, Schneider AM, Yizhak K, Sade-Feldman M, LaSalle T, Sharova T, Xie H, Liu S, Michaud WA, Saad-Beretta R, Yates KB, Iracheta-Vellve A, Spetz JKE, Qin X, Sarosiek KA, Zhang G, Kim JW, Su MY, Cicerchia AM, Rasmussen MQ, Klempner SJ, Juric D, Pai SI, Miller DM, Giobbie-Hurder A, Chen JH, Pelka K, Frederick DT, Stinson S, Ivanova E, Aref AR, Paweletz CP, Barbie DA, Sen DR, Fisher DE, Corcoran RB, Hacohen N, Sorger PK, Flaherty KT, Boland GM, Manguso RT, Jenkins RW. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023 Mar;615(7950):158-167. doi: 10.1038/s41586-023-05704-6. Epub 2023 Jan 12. PMID: 36634707

Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, Leal TA, Bekaii-Saab TS, Paweletz CP, Heavey GA, Christensen JG, Velastegui K, Kheoh T, Der-Torossian H, Klempner SJ. Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C. N Engl J Med. 2023 Jan 5;388(1):44-54. doi: 10.1056/NEJMoa2212419. Epub 2022 Dec 21. PMID: 36546659

Duke-Cohan JS, Akitsu A, Mallis RJ, Messier CM, Lizotte PH, Aster JC, Hwang W, Lang MJ, Reinherz EL. Pre-T cell receptor self-MHC sampling restricts thymocyte dedifferentiation. Nature. 2023 Jan;613(7944):565-574. doi: 10.1038/s41586-022-05555-7. Epub 2022 Nov 21. PMID: 36410718

Yoshida R, Saigi M, Tani T, Springer BF, Shibata H, Kitajima S, Mahadevan NR, Campisi M, Kim W, Kobayashi Y, Thai TC, Haratani K, Yamamoto Y, Sundararaman SK, Knelson EH, Vajdi A, Canadas I, Uppaluri R, Paweletz CP, Miret JJ, Lizotte PH, Gokhale PC, Jänne PA, Barbie DA. MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer. Cancer Res. 2022 Nov 2;82(21):4079-4092. doi: 10.1158/0008-5472.CAN-22-0770. PMID: 36066413

Kitajima S, Tani T, Springer BF, Campisi M, Osaki T, Haratani K, Chen M, Knelson EH, Mahadevan NR, Ritter J, Yoshida R, Köhler J, Ogino A, Nozawa RS, Sundararaman SK, Thai TC, Homme M, Piel B, Kivlehan S, Obua BN, Purcell C, Yajima M, Barbie TU, Lizotte PH, Jänne PA, Paweletz CP, Gokhale PC, Barbie DA. MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. Cancer Cell. 2022 Oct 10;40(10):1128-1144.e8. doi: 10.1016/j.ccell.2022.08.015. Epub 2022 Sep 22. PMID: 36150391

Knelson EH, Ivanova EV, Tarannum M, Campisi M, Lizotte PH, Booker MA, Ozgenc I, Noureddine M, Meisenheimer B, Chen M, Piel B, Spicer N, Obua B, Messier CM, Shannon E, Mahadevan NR, Tani T, Schol PJ, Lee-Hassett AM, Zlota A, Vo HV, Ha M, Bertram AA, Han S, Thai TC, Gustafson CE, Venugopal K, Haggerty TJ, Albertson TP, Hartley AV, Eser PO, Li ZH, Cañadas I, Vivero M, De Rienzo A, Richards WG, Abu-Yousif AO, Appleman VA, Gregory RC, Parent A, Lineberry N, Smith EL, Jänne PA, Miret JJ, Tolstorukov MY, Romee R, Paweletz CP, Bueno R, Barbie DA. Activation of Tumor-Cell STING Primes NK-Cell Therapy. Cancer Immunol Res. 2022 Aug 3;10(8):947-961. doi: 10.1158/2326-6066.CIR-22-0017. PMID: 35678717

Gero TW, Heppner DE, Beyett TS, To C, Azevedo SC, Jang J, Bunnell T, Feru F, Li Z, Shin BH, Soroko KM, Gokhale PC, Gray NS, Jänne PA, Eck MJ, Scott DA. Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. Bioorg Med Chem Lett. 2022 Jul 15;68:128718. doi: 10.1016/j.bmcl.2022.128718. Epub 2022 Apr 1. PMID: 35378251

Berger G, Knelson EH, Jimenez-Macias JL, Nowicki MO, Han S, Panagioti E, Lizotte PH, Adu-Berchie K, Stafford A, Dimitrakakis N, Zhou L, Chiocca EA, Mooney DJ, Barbie DA, Lawler SE. STING activation promotes robust immune response and NK cell-mediated tumor regression in glioblastoma models. Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2111003119. doi: 10.1073/pnas.2111003119. Epub 2022 Jul 5. PMID: 35787058

Awad MM, Le Bruchec Y, Lu B, Ye J, Miller JA, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A. Corrigendum: Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Front Oncol. 2022 Jun 7;12:889996. doi: 10.3389/fonc.2022.889996. eCollection 2022. PMID: 35747830

Son J, Jang J, Beyett TS, Eum Y, Haikala HM, Verano A, Lin M, Hatcher JM, Kwiatkowski NP, Eser PÖ, Poitras MJ, Wang S, Xu M, Gokhale PC, Cameron MD, Eck MJ, Gray NS, Jänne PA. A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer. Cancer Res. 2022 Apr 15;82(8):1633-1645. doi: 10.1158/0008-5472.CAN-21-2693. PMID: 35149586

Ricciuti B, Son J, Okoro JJ, Mira A, Patrucco E, Eum Y, Wang X, Paranal R, Wang H, Lin M, Haikala HM, Li J, Xu Y, Alessi JV, Chhoeu C, Redig AJ, Köhler J, Dholakia KH, Chen Y, Richard E, Nokin MJ, Santamaria D, Gokhale PC, Awad MM, Jänne PA, Ambrogio C. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2022 Apr 14;28(8):1640-1650. doi: 10.1158/1078-0432.CCR-21-2719. PMID: 35091439

To C, Beyett TS, Jang J, Feng WW, Bahcall M, Haikala HM, Shin BH, Heppner DE, Rana JK, Leeper BA, Soroko KM, Poitras MJ, Gokhale PC, Kobayashi Y, Wahid K, Kurppa KJ, Gero TW, Cameron MD, Ogino A, Mushajiang M, Xu C, Zhang Y, Scott DA, Eck MJ, Gray NS, Jänne PA. An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer. 2022 Apr;3(4):402-417. doi: 10.1038/s43018-022-00351-8. Epub 2022 Apr 14. PMID: 35422503

Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D’Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2022 Apr;126(7):1027-1036. doi: 10.1038/s41416-021-01664-8. Epub 2021 Dec 9. PMID: 34887522

Kobayashi Y, Chhoeu C, Li J, Price KS, Kiedrowski LA, Hutchins JL, Hardin AI, Wei Z, Hong F, Bahcall M, Gokhale PC, Jänne PA. Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers. Nature. 2022 Mar;603(7900):335-342. doi: 10.1038/s41586-022-04451-4. Epub 2022 Mar 2. PMID: 35236983.

Williamson DFK, Marris SRN, Rojas-Rudilla V, Bruce JL, Paweletz CP, Oxnard GR, Sholl LM, Dong F. Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR. PLoS One. 2022 Feb 24;17(2):e0264201. doi: 10.1371/journal.pone.0264201. PMID: 35202431

Bahcall M, Paweletz CP, Kuang Y, Taus LJ, Sim T, Kim ND, Dholakia KH, Lau CJ, Gokhale PC, Chopade PR, Hong F, Wei Z, Köhler J, Kirschmeier PT, Guo J, Guo S, Wang S, Jänne PA. Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance. Mol Cancer Ther. 2022 Feb;21(2):322-335. doi: 10.1158/1535-7163.MCT-21-0344. Epub 2021 Nov 17. PMID: 34789563.

Hanna GJ, O’Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ Jr, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478. doi: 10.1158/1078-0432.CCR-21-2635. Epub 2021 Oct 19. PMID: 34667025.

Haikala HM, Lopez T, Köhler J, Eser PO, Xu M, Zeng Q, Teceno TJ, Ngo K, Zhao Y, Ivanova EV, Bertram AA, Leeper BA, Chambers ES, Adeni AE, Taus LJ, Kuraguchi M, Kirschmeier PT, Yu C, Shiose Y, Kamai Y, Qiu Y, Paweletz CP, Gokhale PC, Jänne PA. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd. Cancer Res. 2022 Jan 1;82(1):130-141.
doi: 10.1158/0008-5472.CAN-21-2426. Epub 2021 Sep 21. PMID: 34548332

Cheng ML, Milan MSD, Tamen RM, Bertram AA, Michael KS, Ricciuti B, Kehl KL, Awad MM, Sholl LM, Paweletz CP, Jänne PA. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC. JCO Precis Oncol. 2021 Nov;5:726-732. doi: 10.1200/PO.21.00029. PMID: 34994618.

Konstantinopoulos PA, Cheng SC, Supko JG, Polak M, Wahner-Hendrickson AE, Ivy SP, Bowes B, Sawyer H, Basada P, Hayes M, Curtis J, Horowitz N, Wright AA, Campos SM, Ivanova EV, Paweletz CP, Palakurthi S, Liu JF, D’Andrea AD, Gokhale PC, Chowdhury D, Matulonis UA, Shapiro GI. Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours. Br J Cancer. 2021 Dec 9. doi: 10.1038/s41416-021-01664-8. Epub ahead of print. PMID: 34887522.

Bahcall M, Paweletz CP, Kuang Y, Taus LJ, Sim T, Kim ND, Dholakia KH, Lau CJ, Gokhale PC, Chopade PR, Hong F, Wei Z, Köhler J, Kirschmeier PT, Guo J, Guo S, Wang S, Jänne PA. Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance. Mol Cancer Ther. 2022 Feb;21(2):322-335. doi: 10.1158/1535-7163.MCT-21-0344. Epub 2021 Nov 17. PMID: 34789563

Hanna GJ, O’Neill A, Shin KY, Wong K, Jo VY, Quinn CT, Cutler JM, Flynn M, Lizotte PH, Annino DJ Jr, Goguen LA, Kass JI, Rettig EM, Sethi RKV, Lorch JH, Schoenfeld JD, Margalit DN, Tishler RB, Everett PC, Desai AM, Cavanaugh ME, Paweletz CP, Egloff AM, Uppaluri R, Haddad RI. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478. doi: 10.1158/1078-0432.CCR-21-2635. Epub 2021 Oct 19. PMID: 34667025.

Haikala HM, Lopez T, Köhler J, Eser PO, Xu M, Zeng Q, Teceno TJ, Ngo K, Zhao Y, Ivanova EV, Bertram AA, Leeper BA, Chambers ES, Adeni AE, Taus LJ, Kuraguchi M, Kirschmeier PT, Yu C, Shiose Y, Kamai Y, Qiu Y, Paweletz CP, Gokhale PC, Jänne PA. EGFR Inhibition Enhances the Cellular Uptake and Antitumor-Activity of the HER3 Antibody-Drug Conjugate HER3-DXd. Cancer Res. 2022 Jan 1;82(1):130-141.
doi: 10.1158/0008-5472.CAN-21-2426. Epub 2021 Sep 21. PMID: 34548332

Awad MM, Le Bruchec Y, Lu B, Ye J, Miller J, Lizotte PH, Cavanaugh ME, Rode AJ, Dumitru CD, Spira A. Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study. Front Oncol. 2021 Sep 6;11:696512. doi: 10.3389/fonc.2021.696512. eCollection 2021.
PMID: 34552864

de Klerk LK, Patel AK, Derks S, Pectasides E, Augustin J, Uduman M, Raman N, Akarca FG, McCleary NJ, Cleary JM, Rubinson DA, Clark JW, Fitzpatrick B, Brais LK, Cavanaugh ME, Rode AJ, Jean MG, Lizotte PH, Nazzaro MJ, Severgnini M, Zheng H, Fuchs CS, Enzinger PC, Bass AJ. Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival. J Immunother Cancer. 2021 Sep;9(9):e002472. doi: 10.1136/jitc-2021-002472.
PMID: 34593617

Eser PÖ, Paranal RM, Son J, Ivanova E, Kuang Y, Haikala HM, To C, Okoro JJ, Dholakia KH, Choi J, Eum Y, Ogino A, Missios P, Ercan D, Xu M, Poitras MJ, Wang S, Ngo K, Dills M, Yanagita M, Lopez T, Lin M, Tsai J, Floch N, Chambers ES, Heng J, Anjum R, Santucci AD, Michael K, Schuller AG, Cross D, Smith PD, Oxnard GR, Barbie DA, Sholl LM, Bahcall M, Palakurthi S, Gokhale PC, Paweletz CP, Daley GQ, Jänne PA. Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Sci Transl Med. 2021 Sep;13(609):eabb3738. doi: 10.1126/scitranslmed.abb3738. Epub 2021 Sep 1. PMID: 34516823

Williams PM, Forbes T, P Lund S, Cole KD, He HJ, Karlovich C, Paweletz CP, Stetson D, Yee LM, Connors DE, Keating SM, Destenaves B, Cleveland MH, Lau CJ, Barrett JC, Kelloff GJ, McCormack RT. Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health. JCO Precis Oncol. 2021 Jun 1;5:PO.20.00528. doi: 10.1200/PO.20.00528. PMID: 34250423

Cheng ML, Lau CJ, Milan MSD, Supplee JG, Riess JW, Bradbury PA, Jänne PA, Oxnard GR, Paweletz CP. Plasma ctDNA Response Is an Early Marker of Treatment Effect in Advanced NSCLC. JCO Precis Oncol. 2021 Feb 17;5:PO.20.00419. doi: 10.1200/PO.20.00419. PMID: 34250387

Meador CB, Milan MSD, Hu EY, Awad MM, Rabin MS, Paweletz CP, Hartmaier R, Laus G, Oxnard GR. High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content. JCO Precis Oncol. 2021 Jun 1;5:PO.20.00420. doi: 10.1200/PO.20.00420. PMID: 34250382

Wang ES, Verano AL, Nowak RP, Yuan JC, Donovan KA, Eleuteri NA, Yue H, Ngo KH, Lizotte PH, Gokhale PC, Gray NS, Fischer ES. Acute pharmacological degradation of Helios destabilizes regulatory T cells. Nat Chem Biol. 2021 Jun;17(6):711-717. doi: 10.1038/s41589-021-00802-w. Epub 2021 May 25. PMID: 34035522

Gong B, Li D, Kusko R, Novoradovskaya N, Zhang Y, Wang S, Pabón-Peña C, Zhang Z, Lai K, Cai W, LoCoco JS, Lader E, Richmond TA, Mittal VK, Liu LC, Johann DJ Jr, Willey JC, Bushel PR, Yu Y, Xu C, Chen G, Burgess D, Cawley S, Giorda K, Haseley N, Qiu F, Wilkins K, Arib H, Attwooll C, Babson K, Bao L, Bao W, Lucas AB, Best H, Bhandari A, Bisgin H, Blackburn J, Blomquist TM, Boardman L, Burgher B, Butler DJ, Chang CJ, Chaubey A, Chen T, Chierici M, Chin CR, Close D, Conroy J, Cooley Coleman J, Craig DJ, Crawford E, Del Pozo A, Deveson IW, Duncan D, Eterovic AK, Fan X, Foox J, Furlanello C, Ghosal A, Glenn S, Guan M, Haag C, Hang X, Happe S, Hennigan B, Hipp J, Hong H, Horvath K, Hu J, Hung LY, Jarosz M, Kerkhof J, Kipp B, Kreil DP, Łabaj P, Lapunzina P, Li P, Li QZ, Li W, Li Z, Liang Y, Liu S, Liu Z, Ma C, Marella N, Martín-Arenas R, Megherbi DB, Meng Q, Mieczkowski PA, Morrison T, Muzny D, Ning B, Parsons BL, Paweletz CP, Pirooznia M, Qu W, Raymond A, Rindler P, Ringler R, Sadikovic B, Scherer A, Schulze E, Sebra R, Shaknovich R, Shi Q, Shi T, Silla-Castro JC, Smith M, López MS, Song P, Stetson D, Strahl M, Stuart A, Supplee J, Szankasi P, Tan H, Tang LY, Tao Y, Thakkar S, Thierry-Mieg D, Thierry-Mieg J, Thodima VJ, Thomas D, Tichý B, Tom N, Garcia EV, Verma S, Walker K, Wang C, Wang J, Wang Y, Wen Z, Wirta V, Wu L, Xiao C, Xiao W, Xu S, Yang M, Ying J, Yip SH, Zhang G, Zhang S, Zhao M, Zheng Y, Zhou X, Mason CE, Mercer T, Tong W, Shi L, Jones W, Xu J.
Cross-oncopanel study reveals high sensitivity and accuracy with overall analytical performance depending on genomic regions. Genome Biol. 2021 Apr 16;22(1):109. doi: 10.1186/s13059-021-02315-0. PMID: 33863344

Mahadevan NR, Knelson EH, Wolff JO, Vajdi A, Saigí M, Campisi M, Hong D, Thai TC, Piel B, Han S, Reinhold BB, Duke-Cohan JS, Poitras MJ, Taus LJ, Lizotte PH, Portell A, Quadros V, Santucci AD, Murayama T, Cañadas I, Kitajima S, Akitsu A, Fridrikh M, Watanabe H, Reardon B, Gokhale PC, Paweletz CP, Awad MM, Van Allen EM, Lako A, Wang XT, Chen B, Hong F, Sholl LM, Tolstorukov MY, Pfaff K, Jänne PA, Gjini E, Edwards R, Rodig S, Reinherz EL, Oser MG, Barbie DA.
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discov. 2021 Aug;11(8):1952-1969. doi: 10.1158/2159-8290.CD-20-0913. Epub 2021 Mar 11. PMID: 33707236

Köhler J, Zhao Y, Li J, Gokhale PC, Tiv HL, Knott AR, Wilkens MK, Soroko KM, Lin M, Ambrogio C, Musteanu M, Ogino A, Choi J, Bahcall M, Bertram AA, Chambers ES, Paweletz CP, Bhagwat SV, Manro JR, Tiu RV, Jänne PA. ERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer. Mol Cancer Ther. 2021 Apr;20(4):641-654. doi: 10.1158/1535-7163.MCT-20-0531. Epub 2021 Feb 3. PMID: 33536188

Bertino EM, Gentzler RD, Clifford S, Kolesar J, Muzikansky A, Haura EB, Piotrowska Z, Camidge DR, Stinchcombe TE, Hann C, Malhotra J, Villaruz LC, Paweletz CP, Lau CL, Sholl L, Takebe N, Moscow JA, Shapiro GI, Jänne PA, Oxnard GR. Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903). Clin Cancer Res. 2021 Mar 15;27(6):1604-1611. doi: 10.1158/1078-0432.CCR-20-4084. Epub 2020 Dec 29. PMID: 33376097

Sehgal K, Portell A, Ivanova EV, Lizotte PH, Mahadevan NR, Greene JR, Vajdi A, Gurjao C, Teceno T, Taus LJ, Thai TC, Kitajima S, Liu D, Tani T, Noureddine M, Lau CJ, Kirschmeier PT, Liu D, Giannakis M, Jenkins RW, Gokhale PC, Goldoni S, Pinzon-Ortiz M, Hastings WD, Hammerman PS, Miret JJ, Paweletz CP, Barbie DA.
Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest. 2021 Jan 19;131(2):e135038. doi: 10.1172/JCI135038. PMID: 33151910

Rosen EY, Johnson ML, Clifford SE, Somwar R, Kherani JF, Son J, Bertram AA, Davare MA, Gladstone E, Ivanova EV, Henry DN, Kelley EM, Lin M, Milan MSD, Nair BC, Olek EA, Scanlon JE, Vojnic M, Ebata K, Hechtman JF, Li BT, Sholl LM, Taylor BS, Ladanyi M, Jänne PA, Rothenberg SM, Drilon A, Oxnard GR. Overcoming MET- Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion- Positive Lung Cancer by Combining Selpercatinib with Crizotinib. Clin Cancer Res. 2021 Jan 1;27(1):34-42. doi: 10.1158/1078-0432.CCR-20-2278. Epub 2020 Oct 20. PMID: 33082208

Ogino A, Choi J, Lin M, Wilkens MK, Calles A, Xu M, Adeni AE, Chambers ES, Capelletti M, Butaney M, Gray NS, Gokhale PC, Palakurthi S, Kirschmeier P, Oxnard GR, Sholl LM, Jänne PA. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Mol Oncol. 2021 Jan;15(1):27-42. doi: 10.1002/1878-0261.12673. Epub 2020 Nov 25. PMID: 32191822

Bertino, EM, Gentzler, RD, Clifford, SE, Kolesar, JM, Muzikansky, A, Haura, EB, Piotrowska, Z, Camidge, DR, Stinchcombe, TE, Hann, CL, Malhotra, J, Villaruz, LC, Paweletz, CP, Lau, CJ, Sholl, LM, Takebe, N, Moscow, JA, Shapiro, GI, Janne, PA, Oxnard, GR. Phase IB study of osimertinib in combination with navitoclax in EGFR-mutant NSCLC following resistance to initial EGFR therapy (ETCTN 9903). Clin Cancer Res. 2020.
PubMed PMID:33376097

Lapidot, M, Case, AE, Larios, D, Gandler, HI, Meng, C, Tošić, I, Weisberg, EL, Poitras, MJ, Gokhale, PC, Paweletz, CP, Podar, K, Salgia, R, Saladi, SV, Griffin, JD, Frank, DA, Bueno, R, Sattler, M. Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM). Cancers (Basel). 2020;13 (1).
PubMed PMID:33374980

Bhatt, S, Pioso, MS, Olesinski, EA, Yilma, B, Ryan, JA, Mashaka, T, Leutz, B, Adamia, S, Zhu, H, Kuang, Y, Mogili, A, Louissaint, AJ, Bohl, SR, Kim, AS, Mehta, AK, Sanghavi, S, Wang, Y, Morris, E, Halilovic, E, Paweletz, CP, Weinstock, DM, Garcia, JS, Letai, A. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020;38 (6):872-890.e6.
PubMed PMID:33217342

Sehgal, K, Portell, AJ, Ivanova, EV, Lizotte, PH, Mahadevan, NR, Greene, JR, Vajdi, A, Gurjao, C, Teceno, T, Taus, LJ, Thai, TC, Kitajima, S, Liu, D, Tani, T, Noureddine, M, Lau, CJ, Kirschmeier, PT, Liu, D, Giannakis, M, Jenkins, RW, Gokhale, PC, Goldoni, S, Pinzon-Ortiz, M, Hastings, WD, Hammerman, P, Miret, JJ, Paweletz, CP, Barbie, DA. Dynamic single-cell RNA sequencing identifies immunotherapy persister cells following PD-1 blockade. J Clin Invest. 2020.
PubMed PMID:33151910

Rosen, EY, Johnson, ML, Clifford, SE, Somwar, R, Kherani, JF, Son, J, Bertram, AA, Davare, MA, Gladstone, E, Ivanova, EV, Henry, DN, Kelley, EM, Lin, M, Milan, MSD, Nair, BC, Olek, EA, Scanlon, JE, Vojnic, M, Ebata, K, Hechtman, JF, Li, BT, Sholl, LM, Taylor, BS, Ladanyi, M, Jänne, PA, Rothenberg, SM, Drilon, A, Oxnard, GR. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib. Clin Cancer Res. 2021;27 (1):34-42.
PubMed PMID:33082208

Keegan, A, Ricciuti, B, Garden, P, Cohen, L, Nishihara, R, Adeni, A, Paweletz, C, Supplee, J, Jänne, PA, Severgnini, M, Awad, MM, Walt, DR. Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLC. J Immunother Cancer. 2020;8 (2).
PubMed PMID:33020238

Campisi, M, Sundararaman, SK, Shelton, SE, Knelson, EH, Mahadevan, NR, Yoshida, R, Tani, T, Ivanova, E, Cañadas, I, Osaki, T, Lee, SWL, Thai, T, Han, S, Piel, BP, Gilhooley, S, Paweletz, CP, Chiono, V, Kamm, RD, Kitajima, S, Barbie, DA. Tumor-Derived cGAMP Regulates Activation of the Vasculature. Front Immunol. 2020;11 :2090.
PubMed PMID:33013881

Sholl, LM, Oxnard, GR, Paweletz, CP. Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy. Cancer Res. 2020;80 (16):3197-3199.
PubMed PMID:32606002

Hai, J, Zhang, H, Zhou, J, Wu, Z, Chen, T, Papadopoulos, E, Dowling, CM, Pyon, V, Pan, Y, Liu, JB, Bronson, RT, Silver, H, Lizotte, PH, Deng, J, Campbell, JD, Sholl, LM, Ng, C, Tsao, MS, Thakurdin, C, Bass, AJ, Wong, KK. Generation of Genetically Engineered Mouse Lung Organoid Models for Squamous Cell Lung Cancers Allows for the Study of Combinatorial Immunotherapy. Clin Cancer Res. 2020;26 (13):3431-3442.
PubMed PMID:32209571

Ogino, A, Choi, J, Lin, M, Wilkens, MK, Calles, A, Xu, M, Adeni, AE, Chambers, ES, Capelletti, M, Butaney, M, Gray, NS, Gokhale, PC, Palakurthi, S, Kirschmeier, P, Oxnard, GR, Sholl, LM, Jänne, PA. Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Mol Oncol. 2021;15 (1):27-42.
PubMed PMID:32191822

Weisberg, E, Meng, C, Case, A, Sattler, M, Tiv, HL, Gokhale, PC, Buhrlage, S, Wang, Jinh, A, Kuang, Y, Heavey, GA, Luoma, A, Paweletz, C, Thorner, AR, Wucherpfennig, KW, Qi, J, Brown, M, Sicinski, P, McDonald, TO, Pellman, D, Michor, F, Polyak, K. Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer. Nat Commun. 2020;11 (1):2350.
PubMed PMID:32393766

Ivanova, E, Kuraguchi, M, Xu, M, Portell, AJ, Taus, L, Diala, I, Lalani, AS, Choi, J, Chambers, ES, Li, S, Liu, S, Chen, T, Barbie, TU, Oxnard, GR, Haworth, JJ, Wong, KK, Dahlberg, SE, Aref, AA, Barbie, DA, Bahcall, M, Paweletz, CP, Jänne, PA. Use of ExVivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2020;26 (10):2393-2403.
PubMed PMID:32034078

Recondo, G, Bahcall, M, Spurr, LF, Che, J, Ricciuti, B, Leonardi, GC, Lo, YC, Li, YY, Lamberti, G, Nguyen, T, Milan, MSD, Venkatraman, D, Umeton, R, Paweletz, CP, Albayrak, A, Cherniack, AD, Price, KS, Fairclough, SR, Nishino, M, Sholl, LM, Oxnard, GR, Jänne, PA, Awad, MM. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020;26 (11):2615-2625.
PubMed PMID:32034073

Kurppa, KJ, Liu, Y, To, C, Zhang, T, Fan, M, Vajdi, A, Knelson, EH, Xie, Y, Lim, K, Cejas, P, Portell, A, Lizotte, PH, Ficarro, SB, Li, S, Chen, T, Haikala, HM, Wang, H, Bahcall, M, Gao, Y, Shalhout, S, Boettcher, S, Shin, BH, Thai, T, Wilkens, MK, Tillgren, ML, Mushajiang, M, Xu, M, Choi, J, Bertram, AA, Ebert, BL, Beroukhim, R, Bandopadhayay, P, Awad, MM, Gokhale, PC, Kirschmeier, PT, Marto, JA, Camargo, FD, Haq, R, Paweletz, CP, Wong, KK, Barbie, DA, Long, HW, Gray, NS, Jänne, PA. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway. Cancer Cell. 2020;37 (1):104-122.e12.
PubMed PMID:31935369

Haug, V, Kuang, Y, Tasigiorgos, S, Kollar, B, Mogili, A, Jänne, PA, Talbot, S, Paweletz, CP, Pomahac, B. Circulating Donor-derived Cell-free DNA as a Biomarker in Vascularized Composite Allotransplantation? Transplantation. 2020;104 (3):e79-e80.
PubMed PMID:31596743

Haug, V, Kuang, Y, Tasigiorgos, S, Kollar, B, Mogili, A, Jänne, PA, Talbot, S, Paweletz, CP, Pomahac, B. Circulating donor-derived cell-free DNA as a biomarker in vascularized composite allotransplantation? Transplantation. 2019.
PubMed PMID:31596743

Serrano, C, Leal, A, Kuang, Y, Morgan, JA, Barysauskas, CM, Phallen, J, Triplett, O, Mariño-Enríquez, A, Wagner, AJ, Demetri, GD, Velculescu, VE, Paweletz, CP, Fletcher, JA, George, S. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Clin. Cancer Res. 2019;25 (24):7287-7293.
PubMed PMID:31471313

Parmar, K, Kochupurakkal, BS, Lazaro, JB, Wang, ZC, Palakurthi, S, Kirschmeier, PT, Yang, C, Sambel, LA, Färkkilä, A, Reznichenko, E, Reavis, HD, Dunn, CE, Zou, L, Do, KT, Konstantinopoulos, PA, Matulonis, UA, Liu, JF, D’Andrea, AD, Shapiro, GI. The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clin. Cancer Res. 2019;25 (20):6127-6140.
PubMed PMID:31409614

Stinchcombe, TE, Jänne, PA, Wang, X, Bertino, EM, Weiss, J, Bazhenova, L, Gu, L, Lau, C, Paweletz, C, Jaslowski, A, Gerstner, GJ, Baggstrom, MQ, Graziano, S, Bearden, J 3rd, Vokes, EE. Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial. JAMA Oncol. 2019.
PubMed PMID:31393548

Rangachari, D, To, C, Shpilsky, JE, VanderLaan, PA, Kobayashi, SS, Mushajiang, M, Lau, CJ, Paweletz, CP, Oxnard, GR, Jänne, PA, Costa, DB. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples. J Thorac Oncol. 2019;14 (11):1995-2002.
PubMed PMID:31377341

Rashidian, M, LaFleur, MW, Verschoor, VL, Dongre, A, Zhang, Y, Nguyen, TH, Kolifrath, S, Aref, AR, Lau, CJ, Paweletz, CP, Bu, X, Freeman, GJ, Barrasa, MI, Weinberg, RA, Sharpe, AH, Ploegh, HL. Immuno-PET identifies the myeloid compartment as a key contributor to the outcome of the antitumor response under PD-1 blockade. Proc. Natl. Acad. Sci. U.S.A. 2019;116 (34):16971-16980.
PubMed PMID:31375632

Hanna, GJ, Lau, CJ, Mahmood, U, Supplee, JG, Mogili, AR, Haddad, RI, Jänne, PA, Paweletz, CP. Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer. Oral Oncol. 2019;95 :120-126.
PubMed PMID:31345379

Palakurthi, S, Kuraguchi, M, Zacharek, SJ, Zudaire, E, Huang, W, Bonal, DM, Liu, J, Dhaneshwar, A, DePeaux, K, Gowaski, MR, Bailey, D, Regan, SN, Ivanova, E, Ferrante, C, English, JM, Khosla, A, Beck, AH, Rytlewski, JA, Sanders, C, Laquerre, S, Bittinger, MA, Kirschmeier, PT, Packman, K, Janne, PA, Moy, C, Wong, KK, Verona, RI, Lorenzi, MV. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity. Cancer Immunol Res. 2019;7 (9):1457-1471.
PubMed PMID:31331945

Supplee, JG, Milan, MSD, Lim, LP, Potts, KT, Sholl, LM, Oxnard, GR, Paweletz, CP. Sensitivity of next-generation sequencing assays detecting oncogenic fusions in plasma cell-free DNA. Lung Cancer. 2019;134 :96-99.
PubMed PMID:31320002

Li, BT, Janku, F, Jung, B, Hou, C, Madwani, K, Alden, R, Razavi, P, Reis-Filho, JS, Shen, R, Isbell, JM, Blocker, AW, Eattock, N, Gnerre, S, Satya, RV, Xu, H, Zhao, C, Hall, MP, Hu, Y, Sehnert, AJ, Brown, D, Ladanyi, M, Rudin, CM, Hunkapiller, N, Feeney, N, Mills, GB, Paweletz, CP, Janne, PA, Solit, DB, Riely, GJ, Aravanis, A, Oxnard, GR. Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Ann. Oncol. 2019;30 (4):597-603.
PubMed PMID:30891595

Konstantinopoulos, PA, Barry, WT, Birrer, M, Westin, SN, Cadoo, KA, Shapiro, GI, Mayer, EL, O’Cearbhaill, RE, Coleman, RL, Kochupurakkal, B, Whalen, C, Curtis, J, Farooq, S, Luo, W, Eismann, J, Buss, MK, Aghajanian, C, Mills, GB, Palakurthi, S, Kirschmeier, P, Liu, J, Cantley, LC, Kaufmann, SH, Swisher, EM, D’Andrea, AD, Winer, E, Wulf, GM, Matulonis, UA. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019;20 (4):570-580.
PubMed PMID:30880072

Miret, JJ, Kirschmeier, P, Koyama, S, Zhu, M, Li, YY, Naito, Y, Wu, M, Malladi, VS, Huang, W, Walker, W, Palakurthi, S, Dranoff, G, Hammerman, PS, Pecot, CV, Wong, KK, Akbay, EA. Suppression of Myeloid Cell Arginase Activity leads to Therapeutic Response in a NSCLC Mouse Model by Activating Anti-Tumor Immunity. J Immunother Cancer. 2019;7 (1):32.
PubMed PMID:30728077

Iavarone, C, Zervantonakis, IK, Selfors, LM, Palakurthi, S, Liu, JF, Drapkin, R, Matulonis, UA, Hallberg, D, Velculescu, VE, Leverson, JD, Sampath, D, Mills, GB, Brugge, JS. Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Mol. Cancer Ther. 2019;18 (3):642-655.
PubMed PMID:30679390

Kitajima, S, Ivanova, E, Guo, S, Yoshida, R, Campisi, M, Sundararaman, SK, Tange, S, Mitsuishi, Y, Thai, TC, Masuda, S, Piel, BP, Sholl, LM, Kirschmeier, PT, Paweletz, CP, Watanabe, H, Yajima, M, Barbie, DA. Suppression of STING Associated with LKB1 Loss in KRAS-Driven Lung Cancer. Cancer Discov. 2019;9 (1):34-45.
PubMed PMID:30297358

Zeng, M, Kwiatkowski, NP, Zhang, T, Nabet, B, Xu, M, Liang, Y, Quan, C, Wang, J, Hao, M, Palakurthi, S, Zhou, S, Zeng, Q, Kirschmeier, PT, Meghani, K, Leggett, AL, Qi, J, Shapiro, GI, Liu, JF, Matulonis, UA, Lin, CY, Konstantinopoulos, PA, Gray, NS. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018;7.
PubMed PMID:30422115

Sade-Feldman, M, Yizhak, K, Bjorgaard, SL, Ray, JP, de Boer, CG, Jenkins, RW, Lieb, DJ, Chen, JH, Frederick, DT, Barzily-Rokni, M, Freeman, SS, Reuben, A, Hoover, PJ, Villani, AC, Ivanova, E, Portell, A, Lizotte, PH, Aref, AR, Eliane, JP, Hammond, MR, Vitzthum, H, Blackmon, SM, Li, B, Gopalakrishnan, V, Reddy, SM, Cooper, ZA, Paweletz, CP, Barbie, DA, Stemmer-Rachamimov, A, Flaherty, KT, Wargo, JA, Boland, GM, Sullivan, RJ, Getz, G, Hacohen, N. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018;175 (4):998-1013.e20.
PubMed PMID:30388456

Fitarelli-Kiehl, M, Yu, F, Ashtaputre, R, Leong, KW, Ladas, I, Supplee, J, Paweletz, C, Mitra, D, Schoenfeld, JD, Parangi, S, Makrigiorgos, GM. Denaturation-Enhanced Droplet Digital PCR for Liquid Biopsies. Clin. Chem. 2018;64 (12):1762-1771.
PubMed PMID:30274976

Lizotte, PH, Hong, RL, Luster, TA, Cavanaugh, ME, Taus, LJ, Wang, S, Dhaneshwar, A, Mayman, N, Yang, A, Kulkarni, M, Badalucco, L, Fitzpatrick, E, Kao, HF, Kuraguchi, M, Bittinger, M, Kirschmeier, PT, Gray, NS, Barbie, DA, Jänne, PA. A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing. Cancer Immunol Res. 2018;6 (12):1511-1523.
PubMed PMID:30242021

Kitajima, S, Asahina, H, Chen, T, Guo, S, Quiceno, LG, Cavanaugh, JD, Merlino, AA, Tange, S, Terai, H, Kim, JW, Wang, X, Zhou, S, Xu, M, Wang, S, Zhu, Z, Thai, TC, Takahashi, C, Wang, Y, Neve, R, Stinson, S, Tamayo, P, Watanabe, H, Kirschmeier, PT, Wong, KK, Barbie, DA. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS. Cancer Cell. 2018;34 (3):439-452.e6.
PubMed PMID:30205046

Aref, AR, Campisi, M, Ivanova, E, Portell, A, Larios, D, Piel, BP, Mathur, N, Zhou, C, Coakley, RV, Bartels, A, Bowden, M, Herbert, Z, Hill, S, Gilhooley, S, Carter, J, Cañadas, I, Thai, TC, Kitajima, S, Chiono, V, Paweletz, CP, Barbie, DA, Kamm, RD, Jenkins, RW. 3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade. Lab Chip. 2018;18 (20):3129-3143.
PubMed PMID:30183789

Adeegbe, DO, Liu, S, Hattersley, MM, Bowden, M, Zhou, CW, Li, S, Vlahos, R, Grondine, M, Dolgalev, I, Ivanova, EV, Quinn, MM, Gao, P, Hammerman, PS, Bradner, JE, Diehl, JA, Rustgi, AK, Bass, AJ, Tsirigos, A, Freeman, GJ, Chen, H, Wong, KK. BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non-Small Cell Lung Cancer. Cancer Immunol Res. 2018;6 (10):1234-1245.
PubMed PMID:30087114

Kuang, Y, Siddiqui, B, Hu, J, Pun, M, Cornwell, M, Buchwalter, G, Hughes, ME, Wagle, N, Kirschmeier, P, Jänne, PA, Paweletz, CP, Lin, NU, Krop, IE, Barry, WT, Winer, EP, Brown, M, Jeselsohn, R. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer. 2018;4 :22.
PubMed PMID:30083595

Oxnard, GR, Hu, Y, Mileham, KF, Husain, H, Costa, DB, Tracy, P, Feeney, N, Sholl, LM, Dahlberg, SE, Redig, AJ, Kwiatkowski, DJ, Rabin, MS, Paweletz, CP, Thress, KS, Jänne, PA. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018;4 (11):1527-1534.
PubMed PMID:30073261

Bahcall, M, Awad, MM, Sholl, LM, Wilson, FH, Xu, M, Wang, S, Palakurthi, S, Choi, J, Ivanova, EV, Leonardi, GC, Ulrich, BC, Paweletz, CP, Kirschmeier, PT, Watanabe, M, Baba, H, Nishino, M, Nagy, RJ, Lanman, RB, Capelletti, M, Chambers, ES, Redig, AJ, VanderLaan, PA, Costa, DB, Imamura, Y, Jänne, PA. Amplification of Wild-type KRAS Imparts Resistance to Crizotinib in MET Exon 14 Mutant Non-Small Cell Lung Cancer. Clin. Cancer Res. 2018;24 (23):5963-5976.
PubMed PMID:30072474

Cañadas, I, Thummalapalli, R, Kim, JW, Kitajima, S, Jenkins, RW, Christensen, CL, Campisi, M, Kuang, Y, Zhang, Y, Gjini, E, Zhang, G, Tian, T, Sen, DR, Miao, D, Imamura, Y, Thai, T, Piel, B, Terai, H, Aref, AR, Hagan, T, Koyama, S, Watanabe, M, Baba, H, Adeni, AE, Lydon, CA, Tamayo, P, Wei, Z, Herlyn, M, Barbie, TU, Uppaluri, R, Sholl, LM, Sicinska, E, Sands, J, Rodig, S, Wong, KK, Paweletz, CP, Watanabe, H, Barbie, DA. Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat. Med. 2018;24 (8):1143-1150.
PubMed PMID:30038220

Guibert, N, Tsukada, H, Hwang, DH, Chambers, E, Cibas, ES, Bale, T, Supplee, J, Ulrich, B, Sholl, LM, Paweletz, CP, Oxnard, GR. Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping. Lung Cancer. 2018;122 :72-75.
PubMed PMID:30032849

Oxnard, GR, Paweletz, CP. Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays. JAMA Oncol. 2018;4 (10):1428-1429.
PubMed PMID:30027282

Hanna, GJ, Supplee, JG, Kuang, Y, Mahmood, U, Lau, CJ, Haddad, RI, Jänne, PA, Paweletz, CP. Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer. Ann. Oncol. 2018;29 (9):1980-1986.
PubMed PMID:30010779

Li, S, Liu, S, Deng, J, Akbay, EA, Hai, J, Ambrogio, C, Zhang, L, Zhou, F, Jenkins, RW, Adeegbe, DO, Gao, P, Wang, X, Paweletz, CP, Herter-Sprie, GS, Chen, T, Gutiérrez-Quiceno, L, Zhang, Y, Merlino, AA, Quinn, MM, Zeng, Y, Yu, X, Liu, Y, Fan, L, Aguirre, AJ, Barbie, DA, Yi, X, Wong, KK. Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clin. Cancer Res. 2018;24 (19):4854-4864.
PubMed PMID:29945997

Kuang, Y, O’Connell, A, Sacher, AG, Feeney, N, Alden, RS, Oxnard, GR, Paweletz, CP. Monitoring of Response and Resistance in Plasma of EGFR-Mutant Lung Cancer Using Droplet Digital PCR. Methods Mol. Biol. 2018;1768 :193-207.
PubMed PMID:29717445

Odegaard, JI, Vincent, JJ, Mortimer, S, Vowles, JV, Ulrich, BC, Banks, KC, Fairclough, SR, Zill, OA, Sikora, M, Mokhtari, R, Abdueva, D, Nagy, RJ, Lee, CE, Kiedrowski, LA, Paweletz, CP, Eltoukhy, H, Lanman, RB, Chudova, DI, Talasaz, A. Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies. Clin. Cancer Res. 2018;24 (15):3539-3549.
PubMed PMID:29691297

Liu, HJ, Lizotte, PH, Du, H, Speranza, MC, Lam, HC, Vaughan, S, Alesi, N, Wong, KK, Freeman, GJ, Sharpe, AH, Henske, EP. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy. JCI Insight. 2018;3 (8).
PubMed PMID:29669930

Hu, Y, Ulrich, BC, Supplee, J, Kuang, Y, Lizotte, PH, Feeney, NB, Guibert, NM, Awad, MM, Wong, KK, Jänne, PA, Paweletz, CP, Oxnard, GR. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis. Clin. Cancer Res. 2018;24 (18):4437-4443.
PubMed PMID:29567812

Hanna, GJ, Lizotte, P, Cavanaugh, M, Kuo, FC, Shivdasani, P, Frieden, A, Chau, NG, Schoenfeld, JD, Lorch, JH, Uppaluri, R, MacConaill, LE, Haddad, RI. Frameshift events predict anti-PD-1/L1 response in head and neck cancer. JCI Insight. 2018;3 (4).
PubMed PMID:29467336

Yanagita, M, Luke, JJ, Hodi, FS, Jänne, PA, Paweletz, CP. Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization. Melanoma Res. 2018;28 (2):89-95.
PubMed PMID:29406397

Guibert, N, Hu, Y, Feeney, N, Kuang, Y, Plagnol, V, Jones, G, Howarth, K, Beeler, JF, Paweletz, CP, Oxnard, GR. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Ann. Oncol. 2018;29 (4):1049-1055.
PubMed PMID:29325035

Deng, J, Wang, ES, Jenkins, RW, Li, S, Dries, R, Yates, K, Chhabra, S, Huang, W, Liu, H, Aref, AR, Ivanova, E, Paweletz, CP, Bowden, M, Zhou, CW, Herter-Sprie, GS, Sorrentino, JA, Bisi, JE, Lizotte, PH, Merlino, AA, Quinn, MM, Bufe, LE, Yang, A, Zhang, Y, Zhang, H, Gao, P, Chen, T, Cavanaugh, ME, Rode, AJ, Haines, E, Roberts, PJ, Strum, JC, Richards, WG, Lorch, JH, Parangi, S, Gunda, V, Boland, GM, Bueno, R, Palakurthi, S, Freeman, GJ, Ritz, J, Haining, WN, Sharpless, NE, Arthanari, H, Shapiro, GI, Barbie, DA, Gray, NS, Wong, KK. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018;8 (2):216-233.
PubMed PMID:29101163

Jenkins, RW, Aref, AR, Lizotte, PH, Ivanova, E, Stinson, S, Zhou, CW, Bowden, M, Deng, J, Liu, H, Miao, D, He, MX, Walker, W, Zhang, G, Tian, T, Cheng, C, Wei, Z, Palakurthi, S, Bittinger, M, Vitzthum, H, Kim, JW, Merlino, A, Quinn, M, Venkataramani, C, Kaplan, JA, Portell, A, Gokhale, PC, Phillips, B, Smart, A, Rotem, A, Jones, RE, Keogh, L, Anguiano, M, Stapleton, L, Jia, Z, Barzily-Rokni, M, Cañadas, I, Thai, TC, Hammond, MR, Vlahos, R, Wang, ES, Zhang, H, Li, S, Hanna, GJ, Huang, W, Hoang, MP, Piris, A, Eliane, JP, Stemmer-Rachamimov, AO, Cameron, L, Su, MJ et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018;8 (2):196-215.
PubMed PMID:29101162

Ulrich, BC, Paweletz, CP. Cell-Free DNA in Oncology: Gearing up for Clinic. Ann Lab Med. 2018;38 (1):1-8.
PubMed PMID:29071812

Hu, Y, Alden, RS, Odegaard, JI, Fairclough, SR, Chen, R, Heng, J, Feeney, N, Nagy, RJ, Shah, J, Ulrich, B, Gutierrez, M, Lanman, RB, Garber, JE, Paweletz, CP, Oxnard, GR. Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients. Clin. Cancer Res. 2017;23 (23):7351-7359.
PubMed PMID:28947568

Zervantonakis, IK, Iavarone, C, Chen, HY, Selfors, LM, Palakurthi, S, Liu, JF, Drapkin, R, Matulonis, U, Leverson, JD, Sampath, D, Mills, GB, Brugge, JS. Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nat Commun. 2017;8 (1):365.
PubMed PMID:28848242

Jeselsohn, R, Cornwell, M, Pun, M, Buchwalter, G, Nguyen, M, Bango, C, Huang, Y, Kuang, Y, Paweletz, C, Fu, X, Nardone, A, De Angelis, C, Detre, S, Dodson, A, Mohammed, H, Carroll, JS, Bowden, M, Rao, P, Long, HW, Li, F, Dowsett, M, Schiff, R, Brown, M. Embryonic transcription factor SOX9 drives breast cancer endocrine resistance. Proc. Natl. Acad. Sci. U.S.A. 2017;114 (22):E4482-E4491.
PubMed PMID:28507152

Adeegbe, DO, Liu, Y, Lizotte, PH, Kamihara, Y, Aref, AR, Almonte, C, Dries, R, Li, Y, Liu, S, Wang, X, Warner-Hatten, T, Castrillon, J, Yuan, GC, Poudel-Neupane, N, Zhang, H, Guerriero, JL, Han, S, Awad, MM, Barbie, DA, Ritz, J, Jones, SS, Hammerman, PS, Bradner, J, Quayle, SN, Wong, KK. Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer Discov. 2017;7 (8):852-867.
PubMed PMID:28408401

Zhang, H, Fillmore Brainson, C, Koyama, S, Redig, AJ, Chen, T, Li, S, Gupta, M, Garcia-de-Alba, C, Paschini, M, Herter-Sprie, GS, Lu, G, Zhang, X, Marsh, BP, Tuminello, SJ, Xu, C, Chen, Z, Wang, X, Akbay, EA, Zheng, M, Palakurthi, S, Sholl, LM, Rustgi, AK, Kwiatkowski, DJ, Diehl, JA, Bass, AJ, Sharpless, NE, Dranoff, G, Hammerman, PS, Ji, H, Bardeesy, N, Saur, D, Watanabe, H, Kim, CF, Wong, KK. Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2. Nat Commun. 2017;8 :14922.
PubMed PMID:28387316

Hanna, GJ, Liu, H, Jones, RE, Bacay, AF, Lizotte, PH, Ivanova, EV, Bittinger, MA, Cavanaugh, ME, Rode, AJ, Schoenfeld, JD, Chau, NG, Haddad, RI, Lorch, JH, Wong, KK, Uppaluri, R, Hammerman, PS. Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. Oral Oncol. 2017;67 :61-69.
PubMed PMID:28351582

Matulonis, UA, Wulf, GM, Barry, WT, Birrer, M, Westin, SN, Farooq, S, Bell-McGuinn, KM, Obermayer, E, Whalen, C, Spagnoletti, T, Luo, W, Liu, H, Hok, RC, Aghajanian, C, Solit, DB, Mills, GB, Taylor, BS, Won, H, Berger, MF, Palakurthi, S, Liu, J, Cantley, LC, Winer, E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann. Oncol. 2017;28 (3):512-518.
PubMed PMID:27993796

Tolaney, SM, Ziehr, DR, Guo, H, Ng, MR, Barry, WT, Higgins, MJ, Isakoff, SJ, Brock, JE, Ivanova, EV, Paweletz, CP, Demeo, MK, Ramaiya, NH, Overmoyer, BA, Jain, RK, Winer, EP, Duda, DG. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. Oncologist. 2017;22 (1):25-32.
PubMed PMID:27789775

Liu, JF, Palakurthi, S, Zeng, Q, Zhou, S, Ivanova, E, Huang, W, Zervantonakis, IK, Selfors, LM, Shen, Y, Pritchard, CC, Zheng, M, Adleff, V, Papp, E, Piao, H, Novak, M, Fotheringham, S, Wulf, GM, English, J, Kirschmeier, PT, Velculescu, VE, Paweletz, C, Mills, GB, Livingston, DM, Brugge, JS, Matulonis, UA, Drapkin, R. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin. Cancer Res. 2017;23 (5):1263-1273.
PubMed PMID:27573169

Oxnard, GR, Paweletz, CP, Sholl, LM. Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer. JAMA Oncol. 2017;3 (6):740-741.
PubMed PMID:27541382

Awad, MM, Jones, RE, Liu, H, Lizotte, PH, Ivanova, EV, Kulkarni, M, Herter-Sprie, GS, Liao, X, Santos, AA, Bittinger, MA, Keogh, L, Koyama, S, Almonte, C, English, JM, Barlow, J, Richards, WG, Barbie, DA, Bass, AJ, Rodig, SJ, Hodi, FS, Wucherpfennig, KW, Jänne, PA, Sholl, LM, Hammerman, PS, Wong, KK, Bueno, R. Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. Cancer Immunol Res. 2016;4 (12):1038-1048.
PubMed PMID:27856426

Lizotte, PH, Ivanova, EV, Awad, MM, Jones, RE, Keogh, L, Liu, H, Dries, R, Almonte, C, Herter-Sprie, GS, Santos, A, Feeney, NB, Paweletz, CP, Kulkarni, MM, Bass, AJ, Rustgi, AK, Yuan, GC, Kufe, DW, Jänne, PA, Hammerman, PS, Sholl, LM, Hodi, FS, Richards, WG, Bueno, R, English, JM, Bittinger, MA, Wong, KK. Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes. JCI Insight. 2016;1 (14):e89014.
PubMed PMID:27699239

Bahcall, M, Sim, T, Paweletz, CP, Patel, JD, Alden, RS, Kuang, Y, Sacher, AG, Kim, ND, Lydon, CA, Awad, MM, Jaklitsch, MT, Sholl, LM, Jänne, PA, Oxnard, GR. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov. 2016;6 (12):1334-1341.
PubMed PMID:27694386

Lizotte, PH, Jones, RE, Keogh, L, Ivanova, E, Liu, H, Awad, MM, Hammerman, PS, Gill, RR, Richards, WG, Barbie, DA, Bass, AJ, Bueno, R, English, JM, Bittinger, M, Wong, KK. Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment. Sci Rep. 2016;6 :31745.
PubMed PMID:27539742

Oxnard, GR, Thress, KS, Alden, RS, Lawrance, R, Paweletz, CP, Cantarini, M, Yang, JC, Barrett, JC, Jänne, PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol. 2016;34 (28):3375-82.
PubMed PMID:27354477

Yanagita, M, Redig, AJ, Paweletz, CP, Dahlberg, SE, O’Connell, A, Feeney, N, Taibi, M, Boucher, D, Oxnard, GR, Johnson, BE, Costa, DB, Jackman, DM, Jänne, PA. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin. Cancer Res. 2016;22 (24):6010-6020.
PubMed PMID:27281561

Jia, Y, Yun, CH, Park, E, Ercan, D, Manuia, M, Juarez, J, Xu, C, Rhee, K, Chen, T, Zhang, H, Palakurthi, S, Jang, J, Lelais, G, DiDonato, M, Bursulaya, B, Michellys, PY, Epple, R, Marsilje, TH, McNeill, M, Lu, W, Harris, J, Bender, S, Wong, KK, Jänne, PA, Eck, MJ. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534 (7605):129-32.
PubMed PMID:27251290

Sacher, AG, Paweletz, C, Dahlberg, SE, Alden, RS, O’Connell, A, Feeney, N, Mach, SL, Jänne, PA, Oxnard, GR. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016;2 (8):1014-22.
PubMed PMID:27055085

Wang, S, Blois, A, El Rayes, T, Liu, JF, Hirsch, MS, Gravdal, K, Palakurthi, S, Bielenberg, DR, Akslen, LA, Drapkin, R, Mittal, V, Watnick, RS. Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. Sci Transl Med. 2016;8 (329):329ra34.
PubMed PMID:26962158

Koyama, S, Akbay, EA, Li, YY, Herter-Sprie, GS, Buczkowski, KA, Richards, WG, Gandhi, L, Redig, AJ, Rodig, SJ, Asahina, H, Jones, RE, Kulkarni, MM, Kuraguchi, M, Palakurthi, S, Fecci, PE, Johnson, BE, Janne, PA, Engelman, JA, Gangadharan, SP, Costa, DB, Freeman, GJ, Bueno, R, Hodi, FS, Dranoff, G, Wong, KK, Hammerman, PS. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7 :10501.
PubMed PMID:26883990

Karlovich, C, Goldman, JW, Sun, JM, Mann, E, Sequist, LV, Konopa, K, Wen, W, Angenendt, P, Horn, L, Spigel, D, Soria, JC, Solomon, B, Camidge, DR, Gadgeel, S, Paweletz, C, Wu, L, Chien, S, O’Donnell, P, Matheny, S, Despain, D, Rolfe, L, Raponi, M, Allen, AR, Park, K, Wakelee, H. Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686). Clin. Cancer Res. 2016;22 (10):2386-95.
PubMed PMID:26747242

Maxson, JE, Abel, ML, Wang, J, Deng, X, Reckel, S, Luty, SB, Sun, H, Gorenstein, J, Hughes, SB, Bottomly, D, Wilmot, B, McWeeney, SK, Radich, J, Hantschel, O, Middleton, RE, Gray, NS, Druker, BJ, Tyner, JW. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis. Cancer Res. 2016;76 (1):127-38.
PubMed PMID:26677978

Paweletz, CP, Sacher, AG, Raymond, CK, Alden, RS, O’Connell, A, Mach, SL, Kuang, Y, Gandhi, L, Kirschmeier, P, English, JM, Lim, LP, Jänne, PA, Oxnard, GR. Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients. Clin. Cancer Res. 2016;22 (4):915-22.
PubMed PMID:26459174

Janiszewska, M, Liu, L, Almendro, V, Kuang, Y, Paweletz, C, Sakr, RA, Weigelt, B, Hanker, AB, Chandarlapaty, S, King, TA, Reis-Filho, JS, Arteaga, CL, Park, SY, Michor, F, Polyak, K. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat. Genet. 2015;47 (10):1212-9.
PubMed PMID:26301495

Soucheray, M, Capelletti, M, Pulido, I, Kuang, Y, Paweletz, CP, Becker, JH, Kikuchi, E, Xu, C, Patel, TB, Al-Shahrour, F, Carretero, J, Wong, KK, Jänne, PA, Shapiro, GI, Shimamura, T. Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition. Cancer Res. 2015;75 (20):4372-83.
PubMed PMID:26282169

Tolaney, SM, Tan, S, Guo, H, Barry, W, Van Allen, E, Wagle, N, Brock, J, Larrabee, K, Paweletz, C, Ivanova, E, Janne, P, Overmoyer, B, Wright, JJ, Shapiro, GI, Winer, EP, Krop, IE. Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs. 2015;33 (5):1108-14.
PubMed PMID:26123926

Thress, KS, Paweletz, CP, Felip, E, Cho, BC, Stetson, D, Dougherty, B, Lai, Z, Markovets, A, Vivancos, A, Kuang, Y, Ercan, D, Matthews, SE, Cantarini, M, Barrett, JC, Jänne, PA, Oxnard, GR. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat. Med. 2015;21 (6):560-2.
PubMed PMID:25939061

Castellanos-Rizaldos, E, Paweletz, C, Song, C, Oxnard, GR, Mamon, H, Jänne, PA, Makrigiorgos, GM. Enhanced ratio of signals enables digital mutation scanning for rare allele detection. J Mol Diagn. 2015;17 (3):284-92.
PubMed PMID:25772705

Jänne, PA, Ou, SH, Kim, DW, Oxnard, GR, Martins, R, Kris, MG, Dunphy, F, Nishio, M, O’Connell, J, Paweletz, C, Taylor, I, Zhang, H, Goldberg, Z, Mok, T. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2014;15 (13):1433-41.
PubMed PMID:25456362

Parfenov, M, Pedamallu, CS, Gehlenborg, N, Freeman, SS, Danilova, L, Bristow, CA, Lee, S, Hadjipanayis, AG, Ivanova, EV, Wilkerson, MD, Protopopov, A, Yang, L, Seth, S, Song, X, Tang, J, Ren, X, Zhang, J, Pantazi, A, Santoso, N, Xu, AW, Mahadeshwar, H, Wheeler, DA, Haddad, RI, Jung, J, Ojesina, AI, Issaeva, N, Yarbrough, WG, Hayes, DN, Grandis, JR, El-Naggar, AK, Meyerson, M, Park, PJ, Chin, L, Seidman, JG, Hammerman, PS, Kucherlapati, R, Cancer Genome Atlas Network. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc. Natl. Acad. Sci. U.S.A. 2014;111 (43):15544-9.
PubMed PMID:25313082

Luke, JJ, Oxnard, GR, Paweletz, CP, Camidge, DR, Heymach, JV, Solit, DB, Johnson, BE, Cell Free DNA Working Group. Realizing the potential of plasma genotyping in an age of genotype-directed therapies. J. Natl. Cancer Inst. 2014;106 (8):.
PubMed PMID:25106647

Paweletz, CP, Jänne, PA. Monitoring cancer through the blood. Cancer. 2014;120 (24):3859-61.
PubMed PMID:25103496

Muvaffak, A, Pan, Q, Yan, H, Fernandez, R, Lim, J, Dolinski, B, Nguyen, TT, Strack, P, Wu, S, Chung, R, Zhang, W, Hulton, C, Ripley, S, Hirsch, H, Nagashima, K, Wong, KK, Jánne, PA, Seidel-Dugan, C, Zawel, L, Kirschmeier, PT, Middleton, RE, Morris, EJ, Wang, Y. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol. Cancer Res. 2014;12 (7):1055-66.
PubMed PMID:24752990

Oxnard, GR, Paweletz, CP, Kuang, Y, Mach, SL, O’Connell, A, Messineo, MM, Luke, JJ, Butaney, M, Kirschmeier, P, Jackman, DM, Jänne, PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin. Cancer Res. 2014;20 (6):1698-1705.
PubMed PMID:24429876

Lu, G, Middleton, RE, Sun, H, Naniong, M, Ott, CJ, Mitsiades, CS, Wong, KK, Bradner, JE, Kaelin, WG Jr. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343 (6168):305-9.
PubMed PMID:24292623